Get the Stockscreener App
57.54
0.50%
-0.29
After Hours:
57.54
Praxis Precision Medicines Inc stock is traded at $57.54, with a volume of 285.76K.
It is down -0.50% in the last 24 hours and up +8.26% over the past month.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
See More
Previous Close:
$57.83
Open:
$57.18
24h Volume:
285.76K
Relative Volume:
0.94
Market Cap:
$1.03B
Revenue:
-
Net Income/Loss:
$-123.28M
P/E Ratio:
-18.99
EPS:
-3.03
Net Cash Flow:
$-111.14M
1W Performance:
+1.75%
1M Performance:
+8.26%
6M Performance:
-5.70%
1Y Performance:
+3,265%
1-Day Range:
$55.95
$58.27
1-Week Range:
$55.11
$60.85
52-Week Range:
$0.867
$67.21
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Name
Praxis Precision Medicines Inc
Sector
Industry
Phone
617-300-8460
Address
99 HIGH STREET, 30TH FLOOR, BOSTON
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-23 | Initiated | Truist | Buy |
| Jun-06-22 | Downgrade | Wedbush | Outperform → Neutral |
| Dec-16-21 | Initiated | H.C. Wainwright | Buy |
| Aug-26-21 | Initiated | BofA Securities | Buy |
| Apr-26-21 | Initiated | William Blair | Outperform |
| Nov-11-20 | Initiated | Wedbush | Outperform |
| Nov-10-20 | Initiated | Cowen | Outperform |
| Nov-10-20 | Initiated | Evercore ISI | Outperform |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Praxis Precision Medicines Inc Stock (PRAX) Latest News
Renaissance Technologies LLC Purchases 63,329 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Position Boosted by Marshall Wace LLP - MarketBeat
Fred Alger Management LLC Sells 44,446 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines presents on ulixacaltamide - GlobeNewswire
Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress - StockTitan
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Point72 Asset Management L.P. Grows Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Where are the Opportunities in (PRAX) - Stock Traders Daily
Rhumbline Advisers Grows Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 7.9% - MarketBeat
Ally Bridge Group NY LLC Decreases Stock Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Tri Locum Partners LP Sells 31,175 Shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision’s relutrigine reduces seizures in rare epileptic disorders in phase 2 clinical trials - 2 Minute Medicine
49,510 Shares in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Bought by Bank of New York Mellon Corp - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 2.5% - MarketBeat
TD Asset Management Inc Increases Stock Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
TD Asset Management Inc Grows Stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
(PRAX) Investment Report - Stock Traders Daily
Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 4.7% - MarketBeat
Ballentine Partners LLC Buys New Shares in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Ballentine Partners LLC Makes New Investment in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Receives “Buy” Rating from HC Wainwright - Defense World
HC Wainwright Reaffirms "Buy" Rating for Praxis Precision Medicines (NASDAQ:PRAX) - MarketBeat
Financial Contrast: Praxis Precision Medicines (NASDAQ:PRAX) & Revance Therapeutics (NASDAQ:RVNC) - Defense World
Wedbush Research Analysts Lift Earnings Estimates for Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - Defense World
Ovata Capital Management Ltd Has $1.65 Million Holdings in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat
FY2027 EPS Estimates for Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Raised by Analyst - MarketBeat
Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures - MSN
Praxis Precision Medicines (NASDAQ:PRAX) Trading Down 3.5% - MarketBeat
Financial Health Check: Examining Praxis Precision Medicines Inc (PRAX)’s Key Ratios - The Dwinnex
Praxis Precision Medicines to Participate in Upcoming Investor Conferences - GlobeNewswire
Investing in Praxis Precision Medicines Inc (PRAX) might be an excellent idea, but the stock is currently overvalued/undervalued – US Post News - US Post News
Praxis Precision Medicines to Participate in Upcoming Investor Conferences - StockTitan
Praxis Precision Medicines’ (PRAX) Outperform Rating Reaffirmed at Oppenheimer - Defense World
Forecasting The Future: 14 Analyst Projections For Praxis Precision Medicine - Benzinga
Praxis Precision Medicines (NASDAQ:PRAX) Given Outperform Rating at Oppenheimer - MarketBeat
Praxis Precision Medicines (NASDAQ:PRAX) Shares Up 5.6% - MarketBeat
Praxis Precision shares target raised, holds buy rating on positive study data - Investing.com
PRAX’s Stock Market Journey: A Year of Growth, Decline, and Uncertainty - The InvestChronicle
Praxis Precision shares target raised, holds buy rating on positive study data - Investing.com Canada
Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures - Yahoo Finance
Praxis touts top-line results from the EMBOLD study in epilepsies - The Pharma Letter
Praxis Jumps Wednesday Ahead of Conference Presentation - Baystreet.ca
Praxis Precision shares target raised, holds buy rating on positive study data - Investing.com UK
H.C. Wainwright maintains Buy rating on Praxis Precision shares on epilepsy study success - Investing.com
Praxis Precision Medicines to highlight their Epilepsy - GlobeNewswire
Praxis Precision Medicines to highlight their Epilepsy Portfolio at the International League Against Epilepsy 15th European Epilepsy Congress with six presentations - StockTitan
Praxis Precision Medicines (NASDAQ:PRAX) Given “Buy” Rating at Needham & Company LLC - Defense World
Praxis Precision Medicines (NASDAQ:PRAX) Given Buy Rating at HC Wainwright - Defense World
Praxis reports promising Phase 2 results for epilepsy drug relutrigine - Investing.com India
Praxis Precision shares hold buy rating as study shows promise in epilepsy - Investing.com India
Praxis Precision Medicines Inc Stock (PRAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):